Anemia is associated with major complications for patients with chronic kidney disease (CKD), and the number of American adults who have CKD is now estimated at 37 million. Beside the impact on quality of life and daily functioning, anemia in CKD is also associated with increased morbidity and mortality. Conventional treatment of anemia in these patients has focused on the use of exogenously administered erythropoietin and intravenous iron as required. While the benefits of such therapy are well-established, there are several limitations, including increased risks of cardiovascular and cerebrovascular events.
New
agents are in late-stage development that may address some of the shortcomings of the conventional treatments for CKD. The availability of multiple options will allow clinicians to individualize treatment for different patients. This program brings together experts in managing patients with CKD to discuss some of the emerging therapies; it also provides a short, animated video that demonstrates the pathophysiology and mechanisms of action that may bring new treatments to this field.
This educational activity is an archive of the live satellite symposium held on May 7, 2023. Earn 1.00 / AMA PRA Category 1 Credit™ or 1.00 / CNE Contact Hour. |
Jane S. Davis, CRNP, DNP Nurse Practitioner UAB Medicine University of Alabama at Birmingham Birmingham, AL
Jean Colaneri, ACNP-BC, CNN-NP Nurse Practitioner/Nurse Clinician Acute Adult and Chronic Pediatric Program Albany Medical Center Hospital Albany, NY
Della Connor, PhD, APNP, FNP-BC, FNKF Associate Professor Stephen F. Austin State University Nacogdoches, TX |